APstem Therapeutics was founded in 2017 by scientists from Stanford University, to develop novel technologies and therapies using a new type of adult pluripotent stem cells that can expand rapidly and differentiate into cell lineages originated from three germ layers. Our mission is to develop novel stem cell technology targeting unmet medical needs.
APstem's proprietary stem cells repair lung tissue damaged by COVID-19 while bolstering the body's immune response to fight the novel coronavirus (2019-nCoV). Our stem cells are derived directly from human blood and can be expanded and safely used to meet clinical demand. We are looking for collaboration with clinical sites with COVID-19 patients.